Clinical Trial VICCBRE0767

Title

Predicting Cardiac Effects of Breast Cancer Therapy

Principal Investigator(s)

Daniel Lenihan

Details

  • Protocol No. VICCBRE0767
  • Open Date: 06/11/2008
  • Staging: Phase IV
  • Age Group: Adults
  • Scope: Local
  • Objective: Genetic Aim: To assess whether certain polymorphisms in genes including, but not necessarily limited to, CYBA, RAC2, NCF4, MRP1, MRP2, GTSP and CBR3, increase the relative risk of developing NCI Grade 1 or greater anthracycline cardiotoxicity. Biologic Aim: To assess whether pre-treatment levels of certain biomarkers, including neuregulin, IGF-1, cardiotrophin-1, IL-6, VEGF, hepatocyte growth factor and heparin binding EGF, correlate with relative risk of developing NCI Grade 1 or greater anthracycline cardiotoxicity.
  • Disease Sites: Breast
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University; Meharry Medical College
  • National Clinical Trial ID: NCT00875238
  • Secondary Protocol No: Not Specified

Description

Eligibility

Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.